Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Alvotech made materially false and/or misleading statements and/or failed to disclose that: On November 2, 2025, Alvotech published a press release notifying investors that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for ATV05. The CRL noted that certain deficiencies must be resolved before the BLA for ATV05 can be approved. Alvotech had submitted a Corrective and Preventive Action (CAPA) plan to the FDA following a previous inspection of the Company’s facility. Management stated that Alvotech is “disappointed” in receiving the CRL. Following this news, Alvotech’s stock price fell over 34.2% to close at $5.03 per share on November 3, 2025.
In order to be eligible to join the ALVO class action lawsuit, you must have incurred a loss on shares of Alvotech purchased during the class period listed above.
TOP
